Nymox announces positive efficacy results in Phase 3 trial of NX-1207 Nymox announced new positive efficacy data for U.S. Study NX02-0022, the company's repeat injection study of NX-1207 for BPH. Analysis of symptomatic improvement from repeat injection over a 1 to 2 year period showed a mean improvement of 8.2 points in the AUA BPH Symptom Index Score. Evaluation of safety data from this study confirmed that NX-1207 reinjection treatment was well-tolerated by patients, did not impair sexual function, and has not shown any drug-related significant side effects. Participants in the clinical trial consisted of 160 consecutively treated men who had previously completed participation in an NX-1207 trial for BPH and who volunteered for a subsequent open label injection of NX-1207.
Nymox says Phase 2 NX03-0040 study successfully met pre-determined endpoints Nymox Pharmaceutical Corporation announced results from the completion of the company's U.S. 40 month localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate. The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.The clinical trial commenced in February 2012 at 28 U.S. investigational clinical trial sites and enrolled 147 patients with low grade localized prostate cancer. The study lasted 40 months overall from the first patient randomized to the last patient 18 month endpoints. "These results demonstrate that a single targeted office injection of fexapotide has led to statistically significant improvement in outcomes with much less surgery or radiotherapy required after 18 months. This means a reduction in patient discomfort, and a reduction in permanent side effects and life changes when the more invasive treatments are required," said Paul Averback, CEO of Nymox.